AACR 2012 intro

Article

CancerNetwork brings exclusive coverage of the AACR Annual Meeting, held March 31-April 4, 2012 at McCormick Place in Chicago, Illinois. The meeting will highlight the best and latest findings in all major areas of cancer research. This year's theme is “Accelerating Science: Concept to Clinic,” reflecting the progress and emphasizing the synergy between basic, clinical, and translational research that will continue to lead to effective cancer therapies and prevention strategies. Check below for the most important news to come out of this year's event.

 

CancerNetwork brings exclusive coverage of the AACR Annual Meeting, held March 31-April 4, 2012 at McCormick Place in Chicago, Illinois. The meeting will highlight the best and latest findings in all major areas of cancer research. This year's theme is “Accelerating Science: Concept to Clinic,” reflecting the progress and emphasizing the synergy between basic, clinical, and translational research that will continue to lead to effective cancer therapies and prevention strategies.

Check below for the most important news to come out of this year's event.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Related Content